TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06107998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stethoscope
Description: endotracheal tube cuff will be inflated via stethoscope guidance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audible leak/Balloon palpation
Description: endotracheal tube cuff will be inflated via audible leak/balloon palpation method
Study: NCT05852704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tab
Description: Matching placebo once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
Study: NCT05541939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizagliflozin
Description: Encapsulated or Liquid Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizagliflozin
Description: Encapsulated or Liquid Formulation
Study: NCT04705818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
Study: NCT04727957

Intervention type: OTHER
Intervention: Diagnostic and prognostic models for VA-LRTIs
Description: Diagnostic and prognostic models for VA-LRTIs

Intervention type: OTHER
Intervention: Diagnostic and prognostic models for VA-LRTIs
Description: Diagnostic and prognostic models for VA-LRTIs
Study: NCT06338306

Intervention type: DRUG
Intervention: Tacrolimus（FK506）
Description: Prograf
Study: NCT05511857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-distancing, third-person self-talk.
Description: The participants will engage in self-distancing, third-person self-talk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-immersed, first-person self-talk.
Description: The participants will engage in self-immersed, first-person self-talk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: The participants will engage in a distraction task.
Study: NCT05761353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endermologie
Description: Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.~Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.~-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: Group B will receive negative pressure therapy with~* Pressure: 20-250 mmHg.~* Total treatment period: 6weeks~* A number of sessions: 3sessions/ week. Time of application : 30 min~* In addition to physical therapy program (active range of motion and elevation); hygiene and skin care
Study: NCT05700734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8510
Description: Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8510
Description: Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8510
Description: Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8510
Description: Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
Study: NCT05743530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS - transcutaneous electrical nerve stimulation
Description: Pre-operative day 1 till postoperative day 14.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-operative day 1 till postoperative day 14.
Study: NCT04955782

Intervention type: BEHAVIORAL
Intervention: samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
Description: The volume will be measured by weighing the sample in the container in which it has been collected, it will be a pre-weighed container. The volume will be assessed by aspirating the sample using a non-toxic pre scaled surgical pipette.~The samples will be liquified in an incubator at 37 C. Complete ejaculate liquefaction is normally achieved within 15-30 minutes at room temperature (WHO2010).~pH will be analyzed 30 minutes after collection. pH test strips in range of 6.0-10.0 will be used. A value under 7.0 will indicate lack of alkaline seminal vesicular fluid (pH-Fix 0-14 from Macherey-Nagell,Germany).~The samples concentration and motility will be analyzed in laboratory by Neubauer chamber, morphology will be assessed by RAL Diff-Quik kit (3x0.5L) from RAL Diagnostics, France as per the manufacturers' recommendation.~Vitality will be analyzed by Vital screen, FertiPro N.V. Belgium,as per guidelines of manufacturer

Intervention type: BEHAVIORAL
Intervention: samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
Description: The volume will be measured by weighing the sample in the container in which it has been collected, it will be a pre-weighed container. The volume will be assessed by aspirating the sample using a non-toxic pre scaled surgical pipette.~The samples will be liquified in an incubator at 37 C. Complete ejaculate liquefaction is normally achieved within 15-30 minutes at room temperature (WHO2010).~pH will be analyzed 30 minutes after collection. pH test strips in range of 6.0-10.0 will be used. A value under 7.0 will indicate lack of alkaline seminal vesicular fluid (pH-Fix 0-14 from Macherey-Nagell,Germany).~The samples concentration and motility will be analyzed in laboratory by Neubauer chamber, morphology will be assessed by RAL Diff-Quik kit (3x0.5L) from RAL Diagnostics, France as per the manufacturers' recommendation.~Vitality will be analyzed by Vital screen, FertiPro N.V. Belgium,as per guidelines of manufacturer
Study: NCT05842239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
Study: NCT04846270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENA SmartCare Change Indicator
Description: Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
Study: NCT04577638

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab and Intensity Modulated Radiotherapy (IMRT)
Description: Every included patient will receive the experimental treatment regimen as follows:~* Combination of IMRT 66 Gray (Gy)/24 fractions of 2.75 Gy) and immunotherapy with 3 doses of nivolumab, 240 mg (1th, 3th and 5th week of IMRT) during 5 weeks~* Maintenance treatment by nivolumab 240 mg (Q2W) during 6 months, or until progression and severe toxicity leading to definitive treatment interruption.
Study: NCT05257317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Medicine
Description: Where compression and traction movements will be carried out on these structures.~Technique called CV4, applied on the occipital, and Technique called asynchronous rolling of the temporal bones.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapy
Description: Circular movements will be induced in a frontal and parietal bones
Study: NCT06080516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell exercise
Description: Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell exercise
Description: Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
Study: NCT04906629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
Study: NCT06141785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: An individually targeted nutritional intervention, and a simple home-based physical exercise program. The Nutritional intervention will be delivered by a clinical dietitian, from treatment initiation and throughout the treatment trajectory
Study: NCT05859568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinna-located microphone
Description: Sound processors using a pinna-located microphone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinna-simulated microphone algorithm
Description: Sound processors using a pinna-simulated algorithm
Study: NCT06378385

Intervention type: BEHAVIORAL
Intervention: Childhood Early Oral Aging Syndrome index
Description: Development and validation of a Childhood Early Oral Aging Syndrome index for the primary dentition as a diagnostic and epidemiological survey tool considering the current changes found in the pediatric population.
Study: NCT05054803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ-MSC (XCEL-UMC-BETA)
Description: Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months
Study: NCT04730817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Motor-Cognitive Training System
Description: Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong. The VR training system is designed as a game with 16 progressive levels (anticipating intervention group participants to complete 2 levels per week for 8 weeks) which aim to train their motor and cognitive functions.
Study: NCT06076031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Streaming Media
Description: The aim of this study is to conduct a cross-over randomized clinical trial to compare the effects of with using streaming media (video and audio) on reducing pain medication use, anxiety, pain intensity, and factors related to pain during dressing changes for second-degree burn patients.
Study: NCT05175781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Ketamine is an NMDA receptor antagoni

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT05971771

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: 14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed
Study: NCT05020041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers, given that they are fundamental for the development of habits in the school stage; besides, painted games will be implemented in the school playground.~The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers or manipulation of objects in order to maintain COVID-19 sanitary and safety protocols. The psychomotor circuit includes a line circuit, a jumping sequence game, and a letter spiral. All the games will be implemented in a space within the educational establishment to which the students will have access during recess. The game designs involve activities to develop motor patterns such as jumping with different supports, running, and dynamic balance.
Study: NCT03849534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft occlusal appliance
Description: According to Best Practice in Sweden the soft occlusal appliance is ranked as gold standard for children with mixed or primary dentition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft occlusal appliance
Description: According to Best Practice in Sweden the soft occlusal appliance is ranked as gold standard for children with mixed or primary dentition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft occlusal appliance
Description: According to Best Practice in Sweden the soft occlusal appliance is ranked as gold standard for children with mixed or primary dentition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jaw exercises
Description: The participants do three exercises twice a day. Open and closing mouth against resistance as well as stretch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jaw exercises
Description: The participants do three exercises twice a day. Open and closing mouth against resistance as well as stretch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jaw exercises
Description: The participants do three exercises twice a day. Open and closing mouth against resistance as well as stretch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: The patients are instructed to minimize jaw parafunctions, chewing chewing gum etc, to do exercises, to take pain-killers or NSAIDs etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: The patients are instructed to minimize jaw parafunctions, chewing chewing gum etc, to do exercises, to take pain-killers or NSAIDs etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: The patients are instructed to minimize jaw parafunctions, chewing chewing gum etc, to do exercises, to take pain-killers or NSAIDs etc.
Study: NCT04630977

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-ingredient Pre-workout supplement
Description: Every important issue has been detailed before.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Progressive Resistance Training
Description: The information about it has been detailed in advance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Resistance Training
Description: The information about it has been detailed in advance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: The information about it has been detailed in advance.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nutritional Patterns Guideline
Description: This intervention has also been described in advance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Patterns Guideline
Description: This intervention has also been described in advance.
Study: NCT05754164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training
Description: Mobile app-based attention control training is an effective training method that can help people improve their ability to control attention. It is generally recommended to undergo 4 weeks of training, with 3-4 sessions per week and one day between each session. The specific operational method of this training may vary depending on different applications, but generally, training is presented in the form of a series of tasks. These tasks may involve aspects such as focusing attention, inhibiting interference, and reacting quickly.
Study: NCT04630977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Patterns Guideline
Description: This intervention has also been described in advance.
Study: NCT04744818

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron syrup
Description: Daily supplementation with iron

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin syrup
Description: Daily supplementation with multivitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin syrup
Description: Daily supplementation with multivitamins
Study: NCT05324306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combat application tourniquets (CAT)
Description: CAT tourniquets have been indicated for use in emergency situations revolving around a wounded limb, such as hemorrhage control.22-23 CAT tourniquets are the official tourniquet of the US Army since in 2005.~We will deploy well-studied and FDA approved combat application tourniquets (CAT) on both thighs of volunteer healthy adult subjects while measuring blood pressure in the upper extremities.
Study: NCT05178017

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program
Description: The LEAP program is based on the in-vitro Leukocyte Activation Assay (LAA-MRT) results and initially prepared with the least immune reactive foods and chemicals, and subsequent foods will be added depending on the degree of immune reactivity in a nutritionally balanced manner.
Study: NCT06151808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTR006
Description: All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTR006
Description: All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: XTR006
Description: All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan
Study: NCT05426590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Specular biomicroscopy
Description: Specular microscopy will be done before and 3 weeks after cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Specular biomicroscopy
Description: Specular microscopy will be done before and 3 weeks after cataract surgery
Study: NCT04890548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
Study: NCT06507865

Intervention type: DEVICE
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Description: Patients presenting with thoracic vascular disease that may benefit from the placement of TBE device. The target registry population is patients who are treated with TBE at participating sites. TBE treatment is qualified as receiving the TBE aortic component, at a minimum.
Study: NCT04888962

Intervention type: OTHER
Intervention: OUD
Description: History of opioid use disorder.
Study: NCT05798793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus TP
Description: The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP
Description: The participants will receive docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
Study: NCT06150170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: Proprioceptive exercises were applied to both groups. In addition to these exercises, balance, coordination and strengthening exercises will also be applied to both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: Proprioceptive exercises were applied to both groups. In addition to these exercises, balance, coordination and strengthening exercises will also be applied to both groups.